| NICE Ref |
Title and link to NICE website |
Date issued by DoH |
| TA1046 |
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma |
18/04/25 |
| TA1033 |
Service Notification-Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over NOT RECOMMENDED |
24/03/24 |
| TA992 |
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy |
13-11-24 |
| TA983 |
Pembrolizumab with t trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma |
13-11-24 |
| TA981 |
Voxelotor for treating haemolytic anaemia caused by sickle cell disease – Update Withdrawal of Guidance |
13-11-24 |
| TA955 |
Dupilumab For Treating Moderate to Severe Prurigo Nodularis |
12-04-2024 |
| TA930 |
Lutetium-177 Vipivotide Tetraxetan for Treating Psma-Positive Hormone-Relapsed Metastatic Prostate Cancer After 2 or More Treatments |
21-12-2023 |
| TA928 |
Cabozantinib For Previously Treated Advanced Differentiated Thyroid Cancer Unsuitable For Or Refractory To Radioactive Iodine |
21-12-2023 |
| TA926 |
Baricitinib For Treating Severe Alopecia Areata |
21-12-2023 |
| TA909 |
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer |
14-09-2023 |
| TA900 |
Tixagevimab plus cilgavimab for preventing COVID-19 |
14-09-2023 |
| TA894 |
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma |
14-09-2023 |
| TA892 |
Mosunetuzumab for treating relapsed or refractory follicular lymphoma |
14-09-2023 |
| TA883 |
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma |
14-09-2023 |
| TA881 |
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments |
14-09-2023 |
| TA854 |
Esketamine nasal spray for treatment-resistant depression |
21-04-2023 |
| TA850 |
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy |
21-04-2023 |
| TA831 Reviewed by TA887 |
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer |
21-04-2023 |
| TA812 |
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer |
01-09-2022 |
| TA795 Review of TA491 |
Ibrutinib for treating Waldenstrom’s macroglobulinaemia (review of TA491) |
01-09-2022 |
| TA777 |
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea |
01-09-2022 |
| TA776 |
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea |
01-09-2022 |
| TA724 |
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer |
21-01-2022 |
| TA721 |
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer |
01-09-2022 |
| TA706 |
Ozanimod for treating relapsing–remitting multiple sclerosis |
20-12-2021 |
| TA696 |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
08-06-2021 |
| TA692 |
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (review of TA519) |
01-02-2022 |
| TA669 Reviewed by TA852 |
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies |
16-04-2021 |
| TA650 |
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma |
02-11-2020 |
| TA621 |
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
28-02-2019 |
| TA613 Part Review of TA301 |
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (part review of TA301) |
03-01-2020 |
| TA604 |
Idelalisib for treating refractory follicular lymphoma |
24-10-2019 |
| TA580 |
Enzalutamide for hormone-relapsed non-metastatic prostate cancer |
05-07-2019 |
| TA556 |
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease. |
05-02-2019 |
| TA550 |
Vandetanib for treating medullary thyroid cancer |
10-01-2019 |
| TA546 |
Padeliporfin for untreated localised prostate cancer. |
31-12-2018 |
| TA532 |
Cenegermin for treating neurotrophic keratitis. |
26-10-2018 |
| TA530 |
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. |
26-10-2018 |
| TA515 |
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (review of TA250). |
22-05-2018 |
| TA514 |
Regorafenib for previously treated advanced hepatocellular carcinoma |
21-05-2018 |
| TA506 |
Lesinurad for treating chronic hyperuricaemia in people with gout |
27-03-2018 |
| TA503 |
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
23-03-2018 |
| TA501 |
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. |
08-06-2018 |
| TA494 |
Naltrexone–bupropion for managing overweight and obesity |
04-01-2018 |
| TA489 |
Vismodegib for treating basal cell carcinoma |
14-12-2017 |
| TA440 |
Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine |
12-07-2017 |
| TA 411 |
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
29-11-2016 |
| TA 403 |
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
16-09-2016 |
| TA 399 |
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
03-06-2016 |
| TA 398 |
Lumacaftor and ivacaftor combination therapy for treating cystic fibrosis homozygous for the F508del mutation |
03-06-2016 |
| TA 378 |
Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy |
03-06-2016 |
| TA 371 |
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane |
11-01-2016 |
| TA 368 |
Apremilast for treating moderate to severe plaque psoriasis |
23-12-2015 |
| TA 360 |
Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer |
23-11-2015 |
| TA 355 |
Edoxaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
20-01-2016 |
| TA 338 |
Pomalidomide for treating relapsed and refractory multiple myeloma previously treated with both lenalidomide and bortezomib |
26-05-2015 |
| TA 332 |
Sipuleucel-T for the first line treatment of metastatic hormone relapsed prostate cancer |
09-03-2015 |
| TA 309 |
Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer |
23-05-2014 |
| TA 307 |
Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaplatin-based chemotherapy. |
07-05-2014 |
| TA 299 |
Bosutinib for previously treated chronic myeloid leukaemia |
07-01-2014 |
| TA 296 |
Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene |
22-10-2013 |
| TA 295 |
Everolimus in combination with an aromatase inhibitor for the treatment of HER2 negative, oestrogen receptor positive locally advanced or metastatic breast cancer after prior endocrine therapy. |
24-09-2013 |
| TA 291 |
Pegloticase for treating severe debilitating chronic tophaceous gout |
26-07-2013 |
| TA 289 |
Ruxolitinib for disease-related splenomegaly or symptoms in adult with myelofibrosis |
26-07-2013 |
| TA 285 |
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
27-06-2013 |
| TA 284 |
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
27-06-2013 |
| TA 272 |
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract |
28-02-2013 |
| TA 271 |
Diabetic macular oedema – fluocinolone acetonide intravitreal implant |
28-02-2013 |
| TA 263 |
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
20-12-2012 |
| TA 257 |
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 |
13-09-2012 |
| TA 255 |
Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer |
13-09-2012 |
| TA 250 |
Eribulin- locally advanced or metastatic breast cancer |
13-09-2012 |
| TA 242 |
Colorectal cancer (metastatic) 2nd line- cetuximab, bevacizumab and panitumumab (review) |
13-09-2012 |
| TA 239 |
Breast Cancer (Metastic) – Fultvestrant |
13-09-2012 |
